Across the recent three months, 6 analysts have shared their insights on ResMed (NYSE:RMD), expressing a variety of opinions spanning from bullish to bearish.

The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.

The 12-month price targets, analyzed by analysts, offer insights with an average target of $228.17, a high estimate of $251.00, and a low estimate of $204.00. This upward trend is evident, with the current average reflecting a 2.41% increase from the previous average price target of $222.80.

Decoding Analyst Ratings: A Detailed Look

A clear...